Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05103423 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: BDB-001 Injection
DRUG: Placebo
DRUG: Placebo

Sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd